Fax: +31-10-7038474 or 31-10-7039449.
Early Detection and Diagnosis
At what costs will screening with CT colonography be competitive? A cost-effectiveness approach†
Version of Record online: 24 SEP 2008
Copyright © 2008 Wiley-Liss, Inc.
International Journal of Cancer
Volume 124, Issue 5, pages 1161–1168, 1 March 2009
How to Cite
Lansdorp-Vogelaar, I., van Ballegooijen, M., Zauber, A. G., Boer, R., Wilschut, J. and Habbema, J. D. F. (2009), At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int. J. Cancer, 124: 1161–1168. doi: 10.1002/ijc.24025
Potential conflict of interest: Rob Boer has participated since 1989 in the screening research group at the Department of Public Health of the Erasmus MC. He is affiliated with RAND since 2000. Since 2007, he is a Director of Evidence Based Strategies—Disease Modeling and Economic Evaluation at Pfizer Inc, which develops and sells various medicines for cancer and other diseases. This research and article were not funded or supported by Pfizer.
- Issue online: 18 DEC 2008
- Version of Record online: 24 SEP 2008
- Accepted manuscript online: 24 SEP 2008 12:00AM EST
- Manuscript Accepted: 5 SEP 2008
- Manuscript Received: 27 MAY 2008
- National Cancer Institute. Grant Numbers: U01 CA97426, U01 CA115935
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.